Sermorelin for Weight Loss: Zero Trials, Real History

Sermorelin has a stranger history than most things sold in this market. It was an FDA-approved drug — Geref, from Serono — approved for diagnosing and treating growth hormone deficiency in children. It was discontinued, and FDA formally recorded that the withdrawal was not for safety or effectiveness reasons.^[1] Today it is compounded and sold to adults for weight loss, a use it was never approved for and has never been tested for.

That combination — a real approval history, a clean withdrawal record, and no evidence at all for the thing it is being sold to do — makes it one of the more genuinely confusing products on a telehealth menu. It is also on our menu: 125 of the 556 sellers in this register offer it.

What the FDA record actually says

That last row is the one doing the work, and it is worth understanding why. When a drug is pulled from the market because it was unsafe or did not work, it goes onto a list that bars compounders from using it. Sermorelin is expressly not on that list. Its approval ended for commercial reasons — it did not sell — which leaves a compounding route open that does not exist for a substance like BPC-157.

What it was actually approved to do

Geref's use was diagnosing and treating growth hormone deficiency in children — specifically idiopathic GH deficiency, where a child's pituitary is not producing enough for normal growth.^[2] Sermorelin is a fragment of growth hormone-releasing hormone, and it works upstream: rather than supplying growth hormone, it prompts the pituitary to release more of your own.

That mechanism is real and measurable. Studies from the 1990s established its pharmacokinetics and confirmed it raises growth hormone output.^[3][4] What none of that establishes is what happens to an adult's body weight, which is a different question in a different population.

The evidence for weight loss, in full

There is none. We searched PubMed for sermorelin and weight loss: two results, and neither is a weight-loss study. One concerns a GHRH receptor antagonist — a drug that blocks the pathway rather than stimulating it — in cardiopulmonary disease. The other is a 1996 paper on hypothalamic amenorrhea.

Compare that with what sits beside it on the same menus: semaglutide has STEP-1, 1,961 participants, 68 weeks, published in the New England Journal of Medicine. Tirzepatide has SURMOUNT-1, 2,539 participants. Sermorelin for weight loss has a mechanism story and testimonials.

The argument sellers make, and what is missing from it

1. “It raises your growth hormone.” True, and measurable. Growth hormone does influence body composition — in people who are deficient in it.
2. “Growth hormone reduces fat and builds lean mass.” Established in growth hormone deficiency. Extending it to adults with normal levels is the step where the evidence stops and the inference begins.
3. “So it helps you lose weight.” ⛔ This is the conclusion nobody has tested. A plausible mechanism is a hypothesis, and the history of obesity medicine is largely a history of plausible mechanisms that did not survive a trial.

It is also worth being clear about what is not being claimed here. Sermorelin has a real safety history in its approved population, and there is no suggestion it is dangerous. The gap is between “does something to a hormone axis” and “produces weight loss in adults”, and only a trial closes that gap.

If a seller is offering it to you

• Ask what it is being prescribed for. If the answer is weight loss, ask which study supports that, and notice whether you are given a trial or a mechanism.
• Ask which pharmacy compounds it. The compounding route is legitimate here, so a seller should be able to name the pharmacy without difficulty.
• Ask what it costs beside the thing that does have trials. If it is bundled with a GLP-1, ask what each component contributes and what each costs.
• Ask what happens if it does nothing. A twelve-month prepay on an untested add-on is a different proposition from a monthly one.

Common questions